Effects of pravastatin in 3260 patients with unstable angina: Results from the LIPID study

Lancet

Volumn 356, Issue 9245, 2000, Pages 1871-1875

  Tonkin, Andrew M ^a   Colquhoun, David ^b   Emberson, Jonathan ^c   Hague, Wendy ^c   Keech, Anthony ^c   Lane, Geoffrey ^d   MacMahon, Stephen ^e   Shaw, John ⁱ   Simes, R John ^c   Thompson, Peter L ^f   White, Harvey D ^g   Hunt, David ^h  

^a NATIONAL HEART FOUNDATION OF AUSTRALIA   (Australia)

^b WESLEY HOSPITAL   (Australia)

^c NATIONAL HEALTH AND MEDICAL RESEARCH COUNCIL   (Australia)

^d FREMANTLE HOSPITAL   (Australia)

^e Institute for International Health   (Australia)

^f SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^g GREEN LANE HOSPITAL   (New Zealand)

^h ROYAL MELBOURNE HOSPITAL   (Australia)

ⁱ NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PRAVASTATIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HOSPITAL ADMISSION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; UNSTABLE ANGINA PECTORIS;

EID: 0034597892     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)03257-8     Document Type: Article

References (22)

1. Acute coronary syndromes unstable angina and non-Q wave myocardial infarction
2. Molecular bases of the acute coronary syndromes
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
4. Design features and baseline characteristics of the LIPID (Long-Term Intervention with Pravastatin in Ischaemic Disease) Study a randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris
5. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
6. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S)
7. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
8. Unstable angina diagnosis and management Clinical Practice Guideline Number 10, AHCPR publication 94-0602
9. Is use of a statin agent at the time of presentation for acute myocardial infarction associated with a favourable outcome
10. Early and striking mortality reduction after acute coronary syndromes following lipid lowering therapy
11. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes the RECIFE (Reduction of Cholesterol in Ischemia and Function of the Endothelium) trial
12. HMG-CoA reductase inhibitors decrease CDIIb expression and CDIIb-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolaemia
13. Hyperlipidaema and coronary disease correction of the increased thrombogenic potential with cholesterol reduction
14. Evidence for the benefit of early intervention with pravastatin for secondary prevention of cardiovascular events
15. The short-term results of combined use of pravastatin with thrombolytic therapy in acute myocardial infarction
16. Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction
17. Health system costs of cardiovascular disease and diabetes in Australia, 1993-94
18. Changes in serum lipid concentrations during first 24 hours after myocardial infarction
19. When to start cholesterollowering therapy in patients with coronary heart disease a statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction
20. A European Society of Cardiology survey of secondary prevention of coronary heart disease principal results
21. The Lipid Treatment Assessment Project (L-TAP) a multicenter survey to evaluate the percentages of dyslipidaemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals
22. Clinical outcomes, risk stratification and practice patterns of unstable angina and myocardial infarction without ST elevation Prospective Registry of Acute Ischaemic Syndromes in the UK (PRAIS-UK)